Antiepidermal growth factor receptor radiosensitizers in rectal cancer

Anti-Cancer Drugs

Volumn 22, Issue 4, 2011, Pages 330-340

  Glynne Jones, Robert ^a   Mawdsley, Suzy ^a   Harrison, Mark ^a  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

Anti EGFR; chemotherapy; epidermal growth factor inhibition; radiosensitization; radiosensitizers; rectal adenocarcinoma

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; RADIOSENSITIZING AGENT;

CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG INTERACTION; EVIDENCE BASED PRACTICE; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RADIOSENSITIZATION; RASH; RECTUM CANCER; REVIEW;

COMBINED MODALITY THERAPY; HUMANS; PROTEIN KINASE INHIBITORS; RADIATION-SENSITIZING AGENTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECTAL NEOPLASMS;

EID: 79952989919     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283421290     Document Type: Review

References (115)

1. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995;122:321-326.
2. Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007;25:2198-2204. (Pubitemid 46954643)
3. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109-3116.
4. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al.; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-1740.
5. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemoradiotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355:1114-1123. (Pubitemid 44394918)
6. Mohiuddin M, Winter K, Mitchell E, Hanna N, Yuen A, Nichols C, et al. Randomised phase II study of neoadjuvant combined modality chemoradiation in distal rectal cancer: Radiation Oncology Group Trials 0012. J Clin Oncol 2006;24:650-655. (Pubitemid 46630429)
7. Aschele C, Pinto C, Rosati G, Luppi G, Bonetti A, Miraglia S, et al. Preoperative (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer; pathologic response analysis of the Studio Terapia Adjuvante Retto (STAR)-01 randomized phase III trial. J Clin Oncol 2009;27:18S (part II of II): 804s (Abstract CRA 4008).
8. Roh MS, Colangelo LH, O'Connell MJ, Yothers G, Deutsch M, Allegra CJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP-R03. J Clin Oncol 2009;27:5124-5130.
9. Gé rard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010;28:1638-1644.
10. Gerard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-T4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006;24:4620-4625. (Pubitemid 46630960)
11. Bosset JF, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, et al. Enhanced tumoricidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results of EORTC 22921. J Clin Oncol 2005;23:5620-5627.
12. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342. (Pubitemid 38702844)
13. Adam R, Haller DG, Poston G, Raoul JL, Spano JP, Tabernero J, Van Cutsem E. Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer - an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009. Ann Oncol 2010;21:1579-1584.
14. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563-572.
15. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010;11:38-47.
16. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-28.
17. Nyati MK, Morgan MA, Feng FY, Lawrence TS. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 2006;6:876-885. (Pubitemid 44629899)
18. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37:S3-S8. (Pubitemid 32938123)
19. Uberall I, Kolar Z, Trojec R, Berkovcová J, Hajdúch M. The status and role of ErbB receptors in human cancer. Exp Mol Pathol 2008;84:79-89.
20. Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK, Milas L. Inverse relationship between epidermal growth factor expression and radiocurability of murine carcinomas. Clin Cancer Res 1999;5:2884-2890. (Pubitemid 29493967)
21. Liang K, Ang KK, Milas L, Hunter N, Fan Z. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Biol Phys 2003;57:246-254. (Pubitemid 36959763)
22. Steele RJ, Kelly P, Ellul B, Eremin O. Epidermal growth factor receptor expression in colorectal cancer. Br J Surg 1990;77:1352-1354.
23. Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and MDR gene expression in colorectal cancer. Cancer 1993;71:2454-2460. (Pubitemid 23100476)
24. Khorana AA, Ryan CK, Cox C, Eberly S, Sahasrabudhe DM. Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with stage II and stage III colon carcinoma: a role for the host response in prognosis. Cancer 2003;97:960-968. (Pubitemid 36173146)
25. Hecht JR, Mitchell E, Neubauer MA, Burris HA III, Swanson P, Lopez T, et al. Lack of correlation between epidermal growth factor receptor status and response to panitumumab monotherapy in metastatic colorectal cancer. Clin Cancer Res 2010;16:2205-2213.
26. Kopp R, Rothbauer E, Ruge M, Arnholdt H, Spranger J, Muders M, et al. Clinical implications of the EGF receptor ligand system for tumour progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options. Recent Results Cancer Res 2003;162:115-132.
27. Giralt J, de las Heras M, Cerezo L, Eraso A, Hermosilla E, Velez D, et al. The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy. Radiother Oncol 2005;74:101-108. (Pubitemid 40331866)
28. Bandyopadhyay D, Mandal M, Adam L, Mendelsohn J, Kumar R. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem 1998;273:1568-1573. (Pubitemid 28133681)
29. Meyn RE, Munshi A, Haymach JV, Milas L, Ang KK. Receptor signalling as a regulatory mechanism of DNA repair. Radiother Oncol 2009;92:316-322.
30. Miyaguchi M, Olofsson J, Hellquist HB. Expression of epidermal growth factor receptor in glottic carcinoma and its relation to recurrence after radiotherapy. Clin Otolaryngol Allied Sci 1991;16:466-469.
31. Zhu A, Shaeffer J, Leslie S, Kolm P, El-Mahdi AM. Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive irradiation. Int J Radiat Oncol Biol Phys 1996;34:809-815. (Pubitemid 26089218)
32. Lammering G, Valerie K, Lin PS, Mikkelsen RB, Contessa JN, Feden JP, et al. Radiosensitization of malignant glioma cells through overexpression of dominant negative epidermal growth factor receptor. Clin Cancer Research 2001;7:682-690. (Pubitemid 32707995)
33. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000;6:2166-2174. (Pubitemid 30399181)
34. Zips D, Krause M, Yaromina A, Eicheler W, Schütze C, Gurtner K, et al. Epidermal growth factor receptor inhibitors for radiotherapy: biological rationale and preclinical results. J Pharm Pharmacol 2008;60:1019-1028.
35. Li S, Kim JS, Kim JM, Cho MJ, Yoon WH, Song KS, et al. Epidermal growth factor receptor as a prognostic factor in locally advanced rectal cancer patients treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 2006;65:705-712. (Pubitemid 43795832)
36. Kim JS, Kim JM, Li S, Yoon WH, Song KS, Kim KH, et al. Epidermal growth factor receptor as a predictor of tumour downstaging in locally advanced rectal cancer patients treated with preoperative radiotherapy. Int J Radiation Oncol Biol Phys 2006;66:195-200. (Pubitemid 44175651)
37. Bertolini F, Bengala C, Losi L, Pagano M, Iachetta F, Dealis C, et al. Prognostic and predictive value of baseline and post-treatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007;68:1455-68:1461.
38. Zlobec I, Vuong T, Compton CC, Lugli A, Michel RP, Hayashi S, et al. Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy. Br J Cancer 2008;98:450-456. (Pubitemid 351161259)
39. Azria D, Bibeau F, Barbier N, Zouhair A, Lemanski C, Rouanet P, et al. Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer. BMC Cancer 2005;5:62.
40. Mawdsley S. The role EGFR in predicting clinical outcome in locally advanced carcinoma treated with neoadjuvant chemoradiation. J Clin Oncol - Abstract ASCO 2004 Annual Meeting.
41. Rego R, French AJ, Smyrk TC, Foster DJ, Sargent H, Windschitl MJ, et al. Epidermal growth factor receptor expression in colon cancer with defective DNA mismatch repair. ASCO 2007 Gastrointestinal Cancers Symposium Program/proceedings p294 abstract 422.
42. Debucquoy A, Haustermanns K, Daemen A, Aydin S, Libbrecht L, Gevaert O, et al. Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J Clin Oncol 2009;27:2751-2757.
43. Tournigand C, Lledo G, Delord J, Andre T, Maindrault-Goebel F, Louvet C, et al. Modified (m) FOLFOX7/bevacizumab (B) or modified (m) XELOX/bevacizumab with or without erlotinib (E) in first-line metastatic colorectal cancer (MCRC): results of the feasibility phase of the DREAM-OPTIMOX3 study (GERCOR). J Clin Oncol (Meeting Abstracts) 2007 25:18S (Suppl) abstract 4097.
44. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345. (Pubitemid 38944402)
45. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-1417.
46. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:2311-2319.
47. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapyrefractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-1664. (Pubitemid 46797944)
48. Maughan T, Adams RA, Smith CG, Seymour MT, Wilson R, Meade AM, et al. Addition of cetuximab to oxaliplatin-based combination chemotherapy in patients with K-ras wild-type advanced colorectal cancer (ACRC); a randomised superiority trial (MRC COIN). Eur J Cancer 2009 (Suppl) 7(3);4 (abstract 6LBA).
49. Goldberg RM, Sargent DJ, Thibodeau SN, Mahoney MR, Shield AF, Chan E, et al. Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147. J Clin Oncol (Meeting Abstracts) 2010;28:3508.
50. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634.
51. Douillard EJ, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial [Abstract 10. LBA]ECCO 15 - ESMO 34 2009; Berlin, Germany 20-24 September, 2009.
52. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009;27:672-680.
53. Peeters M, Price T, Hotko Y, Sobrero AF, Ducreaux M, Hotko Y, et al. Randomized phase 3 study of panitumumab with FOLFIRI vs. FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer [Abstract 14. LBA]ECCO 15 - ESMO 34 2009; Berlin, Germany20-24 September, 2009.
54. Williams KJ, Telfer BA, Stratford IJ, Wedge SR. ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor tyrosine kinase inhibitor potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 2002;86:1157-1161. (Pubitemid 34438090)
55. Valentini V, De Paoli A, Gambacorta MA, Mantini G, Ratto C, Vecchio FM, et al. Infusional 5-flourouracil and ZD1839 (gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II trial (1839IL/0092). Int J Radiation Oncol Biol Phys 2008;72:644-649.
56. Blaszkowsky LS, Hong TS, Zhu AX, Kwak EL, Mamon HJ, Shellito PC, et al. A phase I/II study of bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer. J Clin Oncol 2009;27(15S);194S (abstract 4106).
57. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, et al. Cetuximab shows activity in colorectal receptor by immunocytochemistry. J Clin Oncol 2005;23:1803-1810.
58. Hebbar M, Wacrenier A, Desauw C, Romano O, Cattan S, Triboulet JP, Pruvot FR. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs 2006;17:855-857. (Pubitemid 44310182)
59. Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006;24:4914-4921. (Pubitemid 46630920)
60. Lenz HJ. Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events. Oncology (Williston Park) 2006;20(5 Suppl 2):5-13.
61. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-4689. (Pubitemid 19213607)
62. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-671.
63. Kohne C-H, Grunberger T, Bechstein W, Hartmann J, Lang H, Lordick F, et al. Results from the CELIM study: cetuximab plus FOLFOX6 or cetuximab plus FOLFIRI as neoadjuvant treatment for nonresectable colorectal cancer liver metastases. Ann Oncol 2009;20(Suppl 7):vii23 (Abstract 22).
64. Tejpar S, Peeters M, Humblet Y, Vermorken G, De Hertogh W, De Roock J, et al. Relationship of efficacy with K-RAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): the EVERESTexperience (preliminary data). J Clin Oncol 2008;26:178s (suppl; abstr 4001).
65. De RW, Piessevaux H, De SJ, Janssens M, De HG, Personeni N, et al. K-RAS wild type state predicts survival is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncology 2008;19:501-515.
66. Bengala C, Patelli S, Bertolini F, Salvi S, Chiara S, Sonaglio C, et al. Epidermal growth factor receptor gene copy number KRAS mutation and pathological response to preoperative cetuximab, 5FU and radiation therapy in locally advanced rectal cancer. Ann Oncol 2009;20:469-474.
67. Kim SY, Hong YS, Kim DY, Kim TW, Kim JH, Im SA, et al. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter phase II study. Int J Radiat Oncol Biol Phys 2010. [Epub ahead of print].
68. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-5712.
69. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230-3237. (Pubitemid 47325606)
70. Jonker DJ, Karapetis C, Harvison C, O'Callaghan D, Ru RJ, Simes L, et al. High epiregulin (EREG) gene expression plus KRAS wild-type (WT status) is predictive of cetuximab benefit in treatment of advanced colorectal cancer (ACRC): results from the NCIC CTG CO7, a phase III trial of cetuximab versus best supportive care (BSC). Clin Oncol ASCO Annual Meeting Proceedings 2009;27:15s. 4016.
71. Hu-Lieskovan S, Yang D, Grimminger PP, Arnold D, Dellas K, Machiels JH, et al. Use of EGF a + 61G and TS-5'UTR 2R/3R polymorphisms to predict complete pathologic response in locally advanced rectal cancer patients undergoing preoperative cetuximab-based chemoradiation followed by surgery. J Clin Oncol 2010; ASCO Annual Meeting Proceedings (Post-Meeting Edition). 28:151 (May 20 Supplement): abstract 3641.
72. Vallbohmer D, Grimminger PP, Yang D, Danenberg P, Danenberg D, Arnold JH, et al. Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in advanced rectal cancer. J Clin Oncol 2010; ASCO Annual Meeting Proceedings (Post-Meeting Edition). 28:151 (May 20 Supplement): abstract 3563.
73. Oden-Gangloff A, De Fiori F, Bibeau F, Lamy A, Bougeard G, Charbonnier F, et al. TP53 mutations predict disease control in metastases from colorectal cancer treated with cetuximab-based chemotherapy. Br J Cancer 2009;100:330-1335.
74. Fransen K, Klintenas M, Osterstrom A, Dimberg J, Monstein HJ, Soderkvist P. Mutation analysis of the BRAF, ARAF, and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 2004;25:527-533. (Pubitemid 38528645)
75. Birkenkamp-Demtroder K, Olesen SH, Sorensen FB, Laurberg S, Laiho P, Aaltonen LA, Orntoft TF. Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid. Gut 2005;54:374-384. (Pubitemid 40299094)
76. Jonsson M, Ekstrand A, Edekling T, Eberhard J, Grabau D, Borg D, Nilbert M. Experiences from treatment-predictive KRAS testing; high mutation frequency in rectal cancers from females and concurrent mutations in the same tumour. BMC Clinical Pathology 2009;9:1-5.
77. Kalady MF, Sanchez JA, Manilich E, Hammel J, Casey G, Church JM. Divergent oncogenic changes influence survival differences between colon and rectal adenocarcinomas. Dis Colon Rectum 2009;52:1039-1045.
78. Hartley A, Ho KF, McConkey C, Geh JI. Pathological complete response following preoperative chemoradiotherapy in rectal cancer: analysis of phase II/III trials. Br J Radiol 2005;78:934-938. (Pubitemid 41582245)
79. Hughes R, Harrison M, Glynne-Jones R. Could a wait and see policy be justified in T3/4 rectal cancers after chemo-radiotherapy? Acta Oncol 2010;49:378-381.
80. Weiss C, Arnold D, Dellas K, Liersch T, Hipp M, Fietkau R, et al. Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with and without cetuximab a pooled analysis of three prospective phase I-II trials. Int J Radiat Oncol Biol Phys 2010;78:472-478.
81. Hoffheinz R-D, Horisberger K, Woernle C, Wenz F, Kraus-Tiefenbacher U, Kähler G. Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan and radiotherapy as neoadjuvant therapy for rectal cancer. Int J Radiat Oncol Biol Phys 2006;66:1384-1390.
82. Mai SK, Hoffheinz R, Treschl A. Correlation of minimal tumor dose and histopathological regression of rectal cancer after neoadjuvant combined radio-chemo-immunotherapy-results of a prospective phase I/II study (cetuximab capiri-RT). Int J Radiat Oncol Biol Phys 2008;72:S263.
83. Erben P, Horisberger K, Muessle B, Müller MC, Treschl A, Ernst T, et al. mRNA expression of platelet-derived growth factor receptor-beta and C-KIT: correlation with pathologic response to cetuximab-based chemoradiotherapy in patients with rectal cancer. Int J Radiat Oncol Biol Phys 2008;72:1544-1550.
84. Horisberger K, Treschl A, Mai S, Barreto-Miranda M, Kienle P, Ströbel P, et al., MARGIT (Mannheimer Arbeitsgruppe für Gastrointestinale Tumoren). Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a phase II MARGIT trial. Int J Radiat Oncol Biol Phys 2009;74:1487-1493.
85. Czito BG, Willett CG, Bendell JC, Morse MA, Tyler DS, Fernando NH, et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results: PROC ASCO GI. Eur J Cancer 2009;7/2 (Suppl):335 (abstract 6045).
86. Di Fabio F, Pinto C, Maiello E, Pini S, Latiano T, Aschele C, et al. Safety analysis of STARPAN (Star-02) study with panitumumab, 5-fluorouracil, oxaliplatin and concurrent radiotherapy in locally advanced rectal cancer. Eur J Cancer 2009;7/2 (Suppl):335 (abstract 6045).
87. Chung KY, Minsky B, Schrag D, O'Reilly D, D'Adamo E, Hollywood M, et al. Phase I trial of preoperative cetuximab with concurrent continuous infusion 5-fluorouracil and pelvic radiation in patients with local-regionally advanced rectal cancer. J Clin Oncol 2006;24:18S: 161s (abstract 3560).
88. Machiels JP, Sempoux C, Scalliet P, Coche JC, Humblet Y, Van Cutsem E, et al. Phase I/II study of preoperative cetuximab, capecitabine and external beam radiotherapy in patients with rectal cancer. Ann Oncol 2007;18:738-744. (Pubitemid 46523279)
89. Rodel C, Arnold D, Hipp M, Liersch T, Dellas K, Iesalnieks I, et al. Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys 2008;70:1081-1086. (Pubitemid 351296110)
90. Bertolini F, Chiara S, Bengala C, Antognoni P, Dealis C, Zironi S, et al. Neoadjuvant treatment with single agent cetuximab followed by 5-FU, cetuximab and pelvic radiotherapy: a phase II study in locally advanced rectal cancer. Int J Radiation Oncol Biol Phys 2009;73:466-472.
91. Hong YS, Kim DY, Lee KS, Lim SB, Choi HS, Jeong SY, et al. Phase study of preoperative chemoradiation (CRT) with cetuximab, irinotecan capecitabine in patients with locally advanced resectable rectal cancer. Clin Oncol 2007;25:18S:174s (abstract 4045).
92. Cabebe EC, Kuo T, Koong M, Welton M, Shelton A, Kunz PL, et al. Phase I trial of preoperative cetuximab in combination with oxaliplatin, capecitabine, and radiation therapy for locally advanced rectal cancer. J Clin Oncol 2008;26(May 20 suppl) abstract 15019.
93. Eisterer WM, De Vries A, Oefner D, Greil R, Rabl H, Tschmelitsch J, wet Neoadjuvant chemoradiation therapy with capecitabine plus cetuximab external beam radiotherapy in locally advanced rectal cancer (LARC) ABCSG trial R03. J Clin Oncol 2009;27:15S (part I of II) 195s (abstract 4109).
94. Velenik V, Ocvirk J, Oblak I, Anderluh F. Neoadjuvant cetuximab, capecitabine, and radiotherapy (RT) in locally advanced resectable rectal cancer: results phase II trial. J Clin Oncol 2009;27:(abstract e15029).
95. Milas L, Fang FM, Mason KA, Valdecanas D, Hunter N, Koto M, Ang KK. Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation. Int J Radiat Oncol Biol Phys 2007;67:568-572. (Pubitemid 46108328)
96. Hong YS, Kim DY, Lim SB, Choi HS, Jeong SY, Jeong JY, et al. Preoperative chemoradiation with irinotecan and capecitabine in patients with locally advanced resectable rectal cancer: long-term results of a phase II study. Int J Radiat Oncol Biol Phys 2010. [Epub ahead of print].
97. Boulis-Wassif S, Gerard A, Loygue J, Camelot D, Buyse M, Duez N. Final results of a randomised trial on the treatment of rectal cancer with pre-operative radiotherapy alone or in combination with 5 fluorouracil followed by radical surgery. Cancer 1984;53:1811-1818.
98. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, MichalskiW, Bebenek Pudełko M, et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomized trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 2004;72:15-24. (Pubitemid 38952855)
99. Chau I, Brown G, Cunningham D, Tait D, Wotherspoon A, Norman AR, et al. In reply to Glynne-Jones and Sebag-Montefiore. J Clin Oncol 2006;24:4665-4666.
100. Adams RA, Meade AM, Madi A, Fisher D, Kay E, Kenny S, et al. Toxicity associated with combination oxaliplatin plus fluropyrimidine with or without cetuximab in the MRC COIN trial experience. Br J Cancer 2009;100:251-258.
101. Rivera F, Gravalos C, Massuti B, Puente J, Marcuello E, Valladares M, et Cetuximab plus capecitabine as first-line treatment for elderly patients with advanced colorectal cancer (mCRC). Final analysis of activity and survival according to KRAS status: the TTD-06-01 Spanish Cooperative Group trial. Eur J Cancer 2009 (Suppl) 7(2);215 (abstract 0-4004).
102. Brierley JD, Keane TJ, Cummings B, Hao Y. The absence of an adverse effect of prolongation of radiation treatment of primary rectal adenocarcinoma. Clin Oncol (R Coll Radiol) 1996;8:97-101. (Pubitemid 26139007)
103. Hirvikoski P, Auvinen A, Servomaa K, Kiuru A, Rytömaa T, Makkonen K, et al. K-ras and p53 mutations and overexpressions as prognostic factors in female rectal carcinoma. Anticancer Res 1999;19:685-691. (Pubitemid 29168316)
104. Luna-Pé rez P, Segura J, Alvarado I, Labastida S, Santiago-Payán H, Quintero A. Specific c-K-ras gene mutations as a tumour-response marker in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Ann Surg Oncol 2000;7:727-731.
105. Lawrence TS, Davis MA, Tang H-Y, Maybaum J. Fluorodeoxyuridinemediated cytotoxicity and radiosensitisation require S phase progression. Int J Radiat Biol 1996;70:273-280. (Pubitemid 26294834)
106. Guo X, Goessi E, Collie-Duguid ESR, Cassidy J, Wang W, O'Brien V. Cell cycle perturbation and acquired 5-fluorouracil resistance. Anticancer Res 2008;28:9-14. (Pubitemid 351362874)
107. Morelli MP, Cascone T, Troiani T, De Vita F, Orditura M, Laus G, et al. Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Ann Oncol 2005;16(Suppl 4):IV61-IV68. (Pubitemid 43084948)
108. Shewach DS, Lawrence TS. Antimetabolite radiosensitizers. J Clin Oncol 2007;25:4043-4050. (Pubitemid 47492948)
109. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002;8:994-1003. (Pubitemid 34517632)
110. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999;59:1935-1940. (Pubitemid 29186168)
111. Andersson U, Johansson D, Benham-Motlagh P, Johansson M, Malmer B. Treatment schedule is of importance when gefitinib is combined with irradiation of glioma and endothelial cells in vitro. Acta Oncol 2007;46:951-960. (Pubitemid 47537180)
112. Pueyo G, Mesia R, Figueras A, Lozano A, Baro M, Vazquez S, et al. Cetuximab may inhibit tumor growth and angiogenesis induced by ionising radiation: a preclinical rationale for maintenance treatment after radiotherapy. Oncologist 2010;15:976-986.
113. Cascone T, Morelli MP, Morgillo F, Kim WY, Rodolico G, Pepe S, et al. Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. J Cell Physiol 2008;216:698-707.
114. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized phase II trial of panitumumab with infusional fluorouracil, leucovorin and oxaliplatin (FOLFOX 4) verus FOLFOX4 alone as first line treatment in patients with previously untreated metastastic colorectal cancer: the PRIME study. J Clin Oncol 2010;28:4697-4705.
115. Lorenzen S, Schuster T, Porschen R, Al-Batran SE, Hofheinz R, Thuss-Patience P, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2009;20:1667-1673.